Amgen to Delay Humira Biosimilar Until 2023 in Deal With AbbVie

Drug Industry Daily
A A
Amgen has agreed to delay U.S. sales of its cheaper biosimilar to AbbVie’s Humira for the next six years under a settlement with AbbVie.

To View This Article:

Login

Subscribe To Drug Industry Daily